NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_
On January 10, 2025, NextCure, Inc. (NASDAQ: NXTC) made a significant announcement through a press release, indicating the dosing of the first patient in the Phase 1 study of LNCB74. LNCB74 represents a B7-H4-targeting antibody-drug conjugate (ADC), strategically designed as a therapeutic approach for the treatment of multiple cancers. Dr. Udayan Guha, Senior Vice President […]
More Stories
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...
DoubleLine Income Solutions Fund (NYSE:DSL) Shares Pass Below 200-Day Moving Average – Should You Sell?
Shares of DoubleLine Income Solutions Fund (NYSE:DSL – Get Free Report) passed below its 200-day moving average during trading on...